Crown
As of the edition of 20 October 2026, Crown runs 4 drugs, 1 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- Revance Therapeutics, Inc.: acquired in 2025; successor Crown Laboratories, Inc.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 2 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Daxibotulinumtoxina | Ends 2034 (computed from the first US licence) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| SNAP25 Synaptosomal-associated protein 25 | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Crown needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Bones, joints and muscles: 2 trials led
- Skin and connective tissue: 1 trials led